Form D · Biotechnology

Ansa Biotechnologies, Inc.

Emeryville, CA · CIK 0001816722

Offering snapshot reported Dec 10, 2025 · SEC filing

Reported sold: $46.4M
Investors reported: 41
Minimum accepted: $0
First sale: Jun 28, 2024

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$45,199,665 → $46,449,665
Reported investors39 → 41

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Dec 10, 2025	Amendment	$46,449,665	$1,250,000vs Oct 2, 2025	41	SEC filing
Oct 2, 2025	Initial	$45,199,665	No comparison	39	SEC filing
Apr 14, 2022	Initial	$67,724,967	No comparison	23	SEC filing
Oct 15, 2021	Initial	$5,000,000	No comparison	7	SEC filing
Jul 9, 2020	Initial	$4,734,242	No comparison	24	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-559539

Source: Form D, filed Dec 10, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Yanniv Dorone	Director
Jason T. Gammack	Director, Executive
Lily Li	Director
Daniel Lin Arlow	Director, Executive
Matthew Mc Manus	Director
Sebastian Palluk	Executive
Chenny Zhang	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

1198 65 Th Street #250
Emeryville, CA, 94608